losartan has been researched along with Arterial Occlusive Diseases in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Arterial Occlusive Diseases: Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 7.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| "Treatment with losartan may be a viable approach for controlling neointimal hyperplasia at locations (eg, grafts) that are accessible during a surgical procedure." | 5.32 | Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. ( Molnar, K; Moon, MC; Yau, L; Zahradka, P, 2004) |
| " The purpose of the present exploratory study was to determine whether blood pressure-lowering therapy with the combination of the angiotensin receptor blocker losartan plus hydrochlorothiazide (LPH) worsens brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease." | 3.78 | Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv ( Kobayashi, M; Kuroda, H; Ogasawara, K; Ogawa, A; Saura, H; Suzuki, T; Terasaki, K; Yamashita, T, 2012) |
| "Treatment with losartan may be a viable approach for controlling neointimal hyperplasia at locations (eg, grafts) that are accessible during a surgical procedure." | 1.32 | Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. ( Molnar, K; Moon, MC; Yau, L; Zahradka, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saura, H | 1 |
| Ogasawara, K | 1 |
| Suzuki, T | 1 |
| Kuroda, H | 1 |
| Yamashita, T | 1 |
| Kobayashi, M | 1 |
| Terasaki, K | 1 |
| Ogawa, A | 1 |
| Moon, MC | 1 |
| Molnar, K | 1 |
| Yau, L | 1 |
| Zahradka, P | 1 |
2 other studies available for losartan and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusiv
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Occlusive Di | 2012 |
Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury.
Topics: Administration, Topical; Angioplasty, Balloon; Angiotensin Receptor Antagonists; Animals; Antihypert | 2004 |